Systemic and local immunosuppression in patients with high-grade meningiomas

ConclusionsPatients with meningiomas exhibit signs of peripheral immunosuppression, including increased PD-L1 on myeloid cells and elevated MDSC abundance proportional to tumor grade. Additionally, the tumors express substantial PD-L1 proportional to tumor grade. These results suggest a role for immune checkpoint inhibitors targeting the PD-L1/PD-1 pathway in combination with standard therapies for the treatment of high-grade meningiomas.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

Gabriel Griffin, MD, of the Department of Pathology, was honored with a Physician-Scientist Training Award from the Damon Runyon Cancer Research Foundation for his project “Enhancing Cancer Immunotherapy Through Epigenetic Modulation of the Repetitiv
Source: BWH News - Category: Hospital Management Source Type: news
Publication date: Available online 20 July 2019Source: Seminars in Cancer BiologyAuthor(s): Nancy A. Espinoza-Sánchez, Martin GötteAbstractOver the past few decades, understanding how tumor cells evade the immune system and their communication with their tumor microenvironment, has been the subject of intense investigation, with the aim of developing new cancer immunotherapies. The current therapies against cancer such as monoclonal antibodies against checkpoint inhibitors, adoptive T-cell transfer, cytokines, vaccines, and oncolytic viruses have managed to improve the clinical outcome of the patients. However,...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
This study elucidates the potential to use mitochondria from different donors (PAMM) to treat UVR stress and possibly other types of damage or metabolic malfunctions in cells, resulting in not only in-vitro but also ex-vivo applications. Gene Therapy in Mice Alters the Balance of Macrophage Phenotypes to Slow Atherosclerosis Progression https://www.fightaging.org/archives/2019/07/gene-therapy-in-mice-alters-the-balance-of-macrophage-phenotypes-to-slow-atherosclerosis-progression/ Atherosclerosis causes a sizable fraction of all deaths in our species. It is the generation of fatty deposits in blood vessel...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Olbryt M Abstract Melanoma is the most aggressive skin cancer with an increasing number of cases worldwide and curable mostly in its early stage. The improvement in patients' survival in advanced melanoma has been achieved only recently, due to development of new biological drugs for targeted therapies and immunotherapy. Further progress in the treatment of melanoma is clearly dependent on the better understanding of its complex biology. This review describes the most important molecular mechanisms and genetic events underlying skin melanoma development and progression, depicts the way of action of newly d...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Authors: Cabanillas ME, Ryder M, Jimenez C Abstract The treatment of advanced thyroid cancer has undergone rapid evolution in the past decade, with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a number of other commercially available drugs that have been studied for this indication. While most of the FDA approved drugs are anti-angiogenic multikinase inhibitors-vandetanib, cabozantinib, sorafenib, lenvatinib-there are two FDA indications that are mutation specific-dabrafenib/trametinib for BRAF mutated anaplastic thyroid cancer and larotrectinib for NTRK fusion thyroid cancer. Fur...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
Conclusions: It was feasible to measure cfDNA concentration. Despite the limited cohort size, there was a good tendency between cfDNA and treatment course and -response, respectively with the highest levels at progression. PMID: 31320993 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Gilmore E, McCabe N, Kennedy RD, Parkes EE Abstract Historically the development of anticancer treatments has been focused on their effect on tumor cells alone. However, newer treatments have shifted attention to targets on immune cells, resulting in dramatic responses. The effect of DNA repair deficiency on the microenvironment remains an area of key interest. Moreover, established therapies such as DNA damaging treatments such as chemotherapy and PARP inhibitors further modify the tumor microenvironment. Here we describe DNA repair pathways in breast cancer and activation of innate immune pathways in DNA...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Construction of chimeric antigen receptor‑modified T cells targeting EpCAM and assessment of their anti‑tumor effect on cancer cells. Mol Med Rep. 2019 Jul 03;: Authors: Zhou Y, Wen P, Li M, Li Y, Li XA Abstract Colon cancer is a common malignancy worldwide and there is an urgent requirement to develop effective treatment strategies. In recent years, tumor immunotherapy has become a new method of effectively treating tumors. Chimeric antigen receptor (CAR) T cell technology combines the precise targeting specificity of monoclonal antibodies with the strong toxicity and persistence of cytotoxic T ce...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Start-ups like Palleon and NextCure look to broaden the benefits of immuno-oncology with drugs that target a protein family called Siglecs and their glycan ligands
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Publication date: Available online 20 July 2019Source: Trends in Pharmacological SciencesAuthor(s): Zhigang Liu, Yifan Wang, Yuhui Huang, Betty Y.S. Kim, Hong Shan, Depei Wu, Wen JiangImmune cells rely on a functional vascular network to enter tissues. In solid tumors, blood vessels are abnormal and dysfunctional and, thus, immune effector cell infiltration is impaired. Although normalizing the tumor vasculature has been shown to improve the efficacy of cancer immunotherapies, recent studies suggest that enhanced immune stimulation also, in turn, improves tumor vascular normalization. Thus, this new paradigm of immune syst...
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Immunotherapy | Men | Study